EndoDNA, a company specializing in precision health intelligence, has introduced BIOS, an innovative and patented clinical decision-support platform designed exclusively for licensed healthcare professionals. Replacing the company's previous interpretation engine, myDNALive, BIOS provides practitioners in functional, integrative, regenerative, hormone optimization, and longevity medicine with a dynamic, long-term view of a patient's biological profile.

BIOS—short for Biomedical Reasoning and Adaptive Inference Network—takes precision medicine beyond traditional static genetic reports. Instead of offering one-time insights, the platform continuously integrates genomic information, biomarkers, lifestyle factors, symptoms, and other patient data into a unified, evolving clinical dashboard.

According to Len May, Founder and CEO of EndoDNA, healthcare providers have access to unprecedented amounts of biological data but often lack practical tools to translate that information into actionable care strategies. BIOS was developed to bridge this gap by converting complex biological information into structured clinical insights that adapt as patient conditions change, enabling more informed and consistent treatment decisions.

A Pathway-Centered Approach to Genomic Analysis
Unlike many consumer DNA services and generic artificial intelligence platforms that focus on interpreting individual single-nucleotide polymorphisms (SNPs), BIOS evaluates interconnected biological pathways. This systems-based approach allows practitioners to better understand how genetic factors influence overall health.

The platform analyzes key physiological areas, including:

Overall, BIOS evaluates approximately one million validated genetic variants across 21 biological systems and actively manages 214 curated pathways to support real-time clinical decision-making.

Four Integrated Intelligence Networks
Rather than evaluating isolated data points, BIOS uses four interconnected memory networks that collectively create a comprehensive and continuously updated patient profile:

World Network – Incorporates large-scale genomic research and evidence from established resources such as biobanks, CPIC, and PharmGKB.

Experience Network – Leverages aggregated clinical case data to identify interventions that have produced favorable outcomes in similar patient populations.

Opinion Network – Captures practitioner observations, notes, and custom adjustments to personalize recommendations.

Observation Network – Monitors patient-reported outcomes alongside biomarker and laboratory trends over time.
Through a HIPAA-compliant interface, licensed healthcare providers can order DNA testing, generate multiple specialized reports from existing genotype data, integrate laboratory and biomarker information, evaluate pharmacogenomic interactions, and perform natural-language searches of genomic datasets.

Available reporting modules include:

Dr. Allen Lawrence, MA, MD, PhD, noted that while clinicians have long struggled with the challenge of interpreting vast quantities of biological data, BIOS provides a practical framework for transforming that information into meaningful clinical action. By converting genomic and biological inputs into organized, actionable intelligence, the platform supports a more scalable model of precision medicine that enhances decision-making, patient engagement, and individualized care delivery.

Proven Accuracy and Ongoing Innovation
Since its inception, EndoDNA has supported more than 10,000 patients across over nine countries through partnerships with CAP- and CLIA-accredited laboratories. Utilizing Illumina next-generation sequencing technology, the company reports a genotyping accuracy rate of 99.6%.

EndoDNA's intellectual property portfolio includes more than ten issued and pending patents. Among these are a patented methodology for genotyping the endocannabinoid system (ECS) and a proprietary machine-learning framework designed to predict treatment effectiveness using genetic and biometric information.

BIOS is available immediately to licensed healthcare professionals as both a clinical decision-support solution and a research-focused platform.

Luciana Preger attributes her early exposure to her father's medical career as a significant influence on her own path in medicine. Now a physician with over two decades of experience in the pharmaceutical industry, she joined Gilead to advance cancer treatments.
 
"Accompanying my father on hospital rounds in Rio de Janeiro during my childhood, I was deeply moved by the connections he made with patients," recalls Luciana, who is the Vice President of Global Medical Affairs in Oncology. "The emotions I witnessed during those times have stayed with me, and I strive never to forget them."
 
Her work is driven by a commitment to improving patient outcomes and expanding access to medicine. Luciana was drawn to Gilead because of its legacy of increasing global access to transformative medicines, hoping to play a significant role in bridging the gap between scientific innovation and patient care.
 
“To truly transform cancer treatment, we must base oncology advancements on equitable care,” she states. “Scientific innovation is meaningless without clear access, and ensuring access to care is central to all our efforts at Gilead.”
 
Luciana’s career has spanned Brazil, France, and the U.S. Seeking to make a substantial impact in oncology, she saw a unique opportunity in Silicon Valley to work with leading experts in cancer research and treatment.
 
Before joining Gilead, Luciana contributed to the development of over 10 oncology therapies, many of which have demonstrated survival benefits in various cancers. Currently, she is enthusiastic about Gilead’s expanding oncology portfolio, which has reached over 30,000 patients and continues to explore its impact on challenging tumor types.
 
In her role, she guides the strategic direction of Global Medical Affairs initiatives in oncology, advancing the scientific understanding of Gilead’s therapies. Her team facilitates the dissemination of clinical data, collaborates with key opinion leaders, supports external research, and develops educational programs to inform clinical practices.
 
Luciana is proud to be part of a company dedicated to addressing the needs of those requiring its medicines the most. “Our work is significant. We contribute to prolonging lives and addressing the unmet needs of cancer patients worldwide,” she says. “Ultimately, we aim to achieve a cure and restore hope in the face of cancer.”